Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Motivate Robust Growth
WiseGuyReports.com adds “Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Motivate Robust Growth” to its research database.
Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Motivate Robust Growth
Summary
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia – higher blood glucose levels – that outcomes from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated along with lasting damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can easily be classified as having either Form 1 Diabetes Mellitus (T1DM) or Form 2 Diabetes Mellitus (T2DM). Roughly 85-95% of every one of diabetics have actually T2DM.
T2DM treatment has actually been revolutionized in the past decade, especially along with the increased usage of Brand-new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, considerable unmet requirement remains for products that can easily provide much better glycemic regulate too as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardio disease.
Complete report details @ http://ift.tt/1RihfbD
Scope
The current T2DM in the Asia-Pacific (APAC) market consists of novel products, including Jardiance – a SGLT-2 inhibitor; Victoza – a GLP-1 receptor agonist; and Galvus – a DPP-4 inhibitor.
– Just what are the competitive benefits of the existing novel drugs?
With over 500 energetic pipeline molecules, a lot of of the late-phase investigational drug candidates are being evaluated, featuring improved dosing routines and administration routes, in comparison to currently marketed products and combination therapies.
– Which classes of novel drugs are a lot of prominent within the pipeline?
– Is there tough potential for the pipeline to manage unmet calls for within the T2DM market?
Analysis of clinical trials, because 2006, identified that the failure paces of T2DM molecules were highest in Phase II, at 54%, along with the total attrition fee for T2DM at 82.6%.
– Exactly how do failure paces vary by product phase of development, molecule type, and mechanism of action?
– Exactly how do various other factors, such as standard trial duration and trial dimension inspire the costs and risks associated along with product development?
Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to improve in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.
– Which markets make the a lot of considerable supplement to The latest market size?
– Just what are the epidemiology trends in these markets?
– Will certainly Brand-new market entrants bring about substantial modifications in annual therapy costs?
– Exactly how Will certainly various treatment usage designs impact growth in the four assessed Asia-Pacific markets?
Rising T2DM prevalence and the uptake of newer therapies Will certainly bring about considerable market growth, over the forecast period, despite generic sales erosion resulting from patent expirations.
– Will certainly patent expirations or emerging pipeline molecules threaten the commercial victory of existing drugs?
– Which patent expirations Will certainly have actually the a lot of considerable impact on the market?
Reasons to buy
This report Will certainly permit you to –
– Already know the clinical context of T2DM by curious about symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
– Identify the therapeutic strategies, products, and companies that control The latest marketed products landscape and realize gaps and locations of unmet need.
– Identify vital pipeline trends in molecule type, administration route, mechanism of action, and novelty.
– think about market possibilities and potential risks by examining trends in T2DM clinical trial size, duration, and failure fee by phase of development, molecule type, and mechanism of action.
– realize the late-phase pipeline molecules that have actually demonstrated tough therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
– Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, and Japan.
– Locate trends in licensing and co-progress deals about T2DM products and identify the significant strategic consolidations that have actually shaped the commercial landscape.
Order a Get Report Copy @ http://ift.tt/1PwTWGq
Table Of Content
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 9
2.1 ailment Overview 9
2.2 Classification 9
2.3 Symptoms 10
2.4 Etiology 10
2.5 Pathophysiology 11
2.6 Epidemiology 13
2.7 Prognosis 13
2.8 Co-morbidities and Complications 14
2.9 Diagnosis 15
2.10 Assessing Treatment Effectiveness 17
2.11 Treatment 17
2.11.1 Non-insulin T2DM Therapies 19
2.11.2 Insulin T2DM Therapies 22
2.12 Treatment Segments 24
2.12.1 Non-insulin therapies 24
2.12.2 Insulin Therapies 39
3 Marketed Products 43
3.1 Overview 43
3.2 Biguanides 44
3.2.1 Metformin 44
3.3 Sulfonylureas 45
3.4 Thiazolidinediones 47
3.4.1 Pioglitazone 47
3.5 GLP-1 receptor agonists 48
3.5.1 Byetta (exenatide) 48
3.5.2 Bydureon (exenatide) 49
3.5.3 Victoza (liraglutide) 50
3.5.4 Lyxumia (lixisenatide) 51
3.5.5 Tanzeum (albiglutide) 53
3.5.6 Trulicity (dulaglutide) 54
Sample Page of report @ http://ift.tt/1RihfbI
